Metacavir is under clinical development by Guangzhou Yipinhong Pharmaceutical and currently in Phase II for Hepatitis B. According to GlobalData, Phase II drugs for Hepatitis B have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Metacavir’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Metacavir is under development for the treatment of chronic hepatitis B. The drug candidate is administered orally and formulated in the form of enteric capscules. It is a deoxyguanosine analogue which acts by targeting reverse transcriptase.
For a complete picture of Metacavir’s drug-specific PTSR and LoA scores, buy the report here.